摘要
目的探究地西他滨联合全反式维甲酸(ATRA)对老年骨髓增生异常综合征(MDS)的治疗疗效以及安全性。方法前瞻性选取2020年1月至2022年1月海南医学院第一附属医院收治的老年MDS患者107例,按照随机数字表法将其分为观察组(n=53)和对照组(n=54)。对照组患者采用地西他滨单药治疗,观察组采用地西他滨、ATRA联合治疗。对比两组的治疗疗效、输血、生存时间、血液学指标[中性粒细胞计数(NEUT)、血小板计数(PLT)、平均红细胞体积(MCV)、红细胞计数(RBC)]以及不良反应发生情况。结果观察组疾病控制率为66.04%,高于对照组(44.44%),红细胞输注量、血细胞数输注量分别为(7.60±1.03)、(75.36±7.29)U,均低于对照组[(7.95±0.65)、(79.25±10.10)U],差异均有统计学意义(P<0.05)。观察组总生存时间为(24.39±8.02)个月,长于对照组[(17.54±6.11)个月],差异有统计学意义(P<0.05)。治疗后,观察组NEUT、PLT分别为(1.75±0.41)×10^(9)/L、(72.67±9.52)×10^(9)/L,均高于对照组[(1.60±0.19)×10^(9)/L、(67.51±6.34)×10^(9)/L],差异均有统计学意义(P<0.05),而两组MCV、RBC比较,差异均无统计学意义(P>0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论地西他滨联合ATRA较地西他滨单药治疗对老年MDS的治疗效果更佳,可降低不良反应发生率,延长患者的生存时间,值得在临床治疗中推广应用。
Objective To investigate the efficacy and safety of decitabine and all-trans retinoic acid(ATRA)combined in the treatment of elderly myelodysplastic syndromes(MDS).Methods A total of 107 elderly MDS patients admitted to the First Affiliated Hospital of Hainan Medical College from January 2020 to January 2022 were prospectively selected and divided into an observation group(n=53)and a control group(n=54)according to the random number table method.The patients in the control group were treated with decitabine,and the patients in the observation group were treated with decitabine and ATRA.The therapeutic efficacy,the blood transfusion,survival time,hematological indicators[neutrophil count(NEUT),platelet count(PLT),mean red blood cell volume(MCV),red blood cell count(RBC)]and adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 66.04%,which was higher than that of the control group(44.44%),and the infusion amount of red blood cell and blood cell count were(7.60±1.03),(75.36±7.29)U,respectively,which were lower than those of the control group[(7.95±0.65),(79.25±10.10)U],the differences were statistically significant(P<0.05).The overall survival time of the observation group was(24.39±8.02)months,which was longer than that of the control group[(17.54±6.11)months],the difference was statistically significant(P<0.05).After treatment,NEUT and PLT in observation group were(1.75±0.41)×10^(9)/L,(72.67±9.52)×10^(9)/L,respectively,which were higher than those in the control group[(1.60±0.19)×10^(9)/L,(67.51±6.34)×10^(9)/L],the differences were statistically significant(P<0.05),however,there was no statistically significant difference in MCV and RBC between the two groups(P>0.05).There was no statistically difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with decitabine monotherapy,decitabine combined with ATRA has better therapeutic effect on elderly MDS,reduces the incidence of adverse reacti
作者
刘淑芳
赵映
李丽娜
LIU Shu-fang;ZHAO Ying;LI Li-na(Department of Hematology,The First Affiliated Hospital of Hainan Medical College,Haikou Hainan 570100,China)
出处
《临床和实验医学杂志》
2023年第12期1263-1266,共4页
Journal of Clinical and Experimental Medicine
基金
海南省卫生健康行业科研项目(编号:21A200060)。
